Michael Zinda, EVP, Chief Science Officer at Repare Therapeutics Inc. (RPTX), sold 533 shares at $11.30 ($6K) on 2022-03-15, disclosed to the SEC on 2022-03-16.
Scheduled sale ($6k) by EVP, Chief Science Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| RPTX | SELL | 2024-03-27 | $6K | — | Filing → |
| RPTX | SELL | 2023-06-09 | $189K | — | Filing → |
| RPTX | SELL | 2023-06-07 | $14K | — | Filing → |